| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
1Strategic Director, Cancer Surveillance, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
2Manager, Surveillance Information Services, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
3Vice President, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
4Senior Epidemiologist, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
5Epidemiologist, Mortality Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland
6Vice President Emeritus, Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia
Corresponding author: Ahmedin Jemal, DVM, PhD, Surveillance and Health Policy Research, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303-1002; ahmedin.jemal{at}cancer.org
DISCLOSURES: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors report no conflicts of interest.
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are standardized by age to the 2000 United States standard million population. A total of 1,479,350 new cancer cases and 562,340 deaths from cancer are projected to occur in the United States in 2009. Overall cancer incidence rates decreased in the most recent time period in both men (1.8% per year from 2001 to 2005) and women (0.6% per year from 1998 to 2005), largely because of decreases in the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancer sites in women (breast and colorectum). Overall cancer death rates decreased in men by 19.2% between 1990 and 2005, with decreases in lung (37%), prostate (24%), and colorectal (17%) cancer rates accounting for nearly 80% of the total decrease. Among women, overall cancer death rates between 1991 and 2005 decreased by 11.4%, with decreases in breast (37%) and colorectal (24%) cancer rates accounting for 60% of the total decrease. The reduction in the overall cancer death rates has resulted in the avoidance of about 650,000 deaths from cancer over the 15-year period. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year. Although progress has been made in reducing incidence and mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons younger than 85 years of age. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment. CA Cancer J Clin 2009;59:225-249. � 2009 American Cancer Society, Inc.
This article has been cited by other articles:
|
|
 |
|
  D. J. Shields, S. Niessen, E. A. Murphy, A. Mielgo, J. S. Desgrosellier, S. K. M. Lau, L. A. Barnes, J. Lesperance, M. Bouvet, D. Tarin, et al. RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia PNAS, February 2, 2010; 107(5): 2189 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, S. L. Zheng, S. D. Isaacs, K. E. Wiley, F. Wiklund, J. Sun, A. K. Kader, G. Li, L. D. Purcell, S.-T. Kim, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer PNAS, February 2, 2010; 107(5): 2136 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Simon Treatment of Older Patients With Non-Small-Cell Lung Cancer: Walking the Therapeutic Tightrope J. Clin. Oncol., February 1, 2010; 28(4): 523 - 526. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Bunn Jr. Optimal Therapy for Elderly Patients with Early Stage Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., February 1, 2010; 181(3): 201 - 202. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hou, E. Bojdani, and M. Xing Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 820 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Beuten, J. A.L. Gelfond, J. L. Franke, S. Shook, T. L. Johnson-Pais, I. M. Thompson, and R. J. Leach Single and Multivariate Associations of MSR1, ELAC2, and RNASEL with Prostate Cancer in an Ethnic Diverse Cohort of Men Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 588 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Melkamu, X. Zhang, J. Tan, Y. Zeng, and F. Kassie Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol Carcinogenesis, February 1, 2010; 31(2): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Stany, G. L. Maxwell, and G. S. Rose Clinical Decision Making Using Ovarian Cancer Risk Assessment Am. J. Roentgenol., February 1, 2010; 194(2): 337 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dutta, F.-q. Wang, A. C. Fleischer, and D. A. Fishman New Frontiers for Ovarian Cancer Risk Evaluation: Proteomics and Contrast-Enhanced Ultrasound Am. J. Roentgenol., February 1, 2010; 194(2): 349 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, P. Kraft, M. Gross, K. Helzlsouer, H. B. Bueno-de-Mesquita, E. Steplowski, R. Z. Stolzenberg-Solomon, A. A. Arslan, E. J. Jacobs, A. LaCroix, et al. Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium Cancer Res., February 1, 2010; 70(3): 1015 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Makawita and E. P. Diamandis The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometry-Based Approaches: Current Strategies for Candidate Verification Clin. Chem., February 1, 2010; 56(2): 212 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Clifford and J. DiGiovanni The Promise of Natural Products for Blocking Early Events in Skin Carcinogenesis Cancer Prevention Research, February 1, 2010; 3(2): 132 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Moreno The Sex-Determining Region Y-Box 4 and Homeobox C6 Transcriptional Networks in Prostate Cancer Progression: Crosstalk with the Wnt, Notch, and PI3K Pathways Am. J. Pathol., February 1, 2010; 176(2): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Goode, M. J. Maurer, T. A. Sellers, C. M. Phelan, K. R. Kalli, B. L. Fridley, R. A. Vierkant, S. M. Armasu, K. L. White, G. L. Keeney, et al. Inherited Determinants of Ovarian Cancer Survival Clin. Cancer Res., February 1, 2010; 16(3): 995 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khan, V. M. Adhami, and H. Mukhtar Apoptosis by dietary agents for prevention and treatment of prostate cancer Endocr. Relat. Cancer, January 29, 2010; 17(1): R39 - R52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Santillan, J. L. Messina, S. S. Marzban, G. Crespo, V. K. Sondak, and J. S. Zager Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions J. Clin. Oncol., January 20, 2010; 28(3): 481 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dandona, F. Gao, D. C. Linehan, and A. Wang-Gillam Re: ABO Blood Group and the Risk of Pancreatic Cancer J Natl Cancer Inst, January 20, 2010; 102(2): 135 - 137. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Brune, B. Lau, E. Palmisano, M. Canto, M. G. Goggins, R. H. Hruban, and A. P. Klein Importance of Age of Onset in Pancreatic Cancer Kindreds J Natl Cancer Inst, January 20, 2010; 102(2): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, K. B. Niendorf, D. Patel, A. Blackford, F. Marroni, A. J. Sober, G. Parmigiani, and H. Tsao Estimating CDKN2A Carrier Probability and Personalizing Cancer Risk Assessments in Hereditary Melanoma Using MelaPRO Cancer Res., January 15, 2010; 70(2): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. DeAngelis and P. B. Fontanarosa US Preventive Services Task Force and Breast Cancer Screening JAMA, January 13, 2010; 303(2): 172 - 173. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cheville Prevention of lymphoedema after axillary surgery for breast cancer BMJ, January 12, 2010; 340(jan12_1): b5235 - b5235. [Full Text]
|
|
|
|
|
|
P. C. Albertsen Does the Benefit Justify the Risk? J Natl Cancer Inst, January 6, 2010; 102(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wu, P.-C. Chang, J. C. Yang, C.-Y. Chu, L.-Y. Wang, N.-T. Chen, A.-H. Ma, S. J. Desai, S. H. Lo, C. P. Evans, et al. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors Genes & Cancer, January 1, 2010; 1(1): 40 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yan, E. L. Spitznagel, and M. C. Bosland Soy Consumption and Colorectal Cancer Risk in Humans: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 148 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fedirko, R. M. Bostick, Q. Long, W. D. Flanders, M. L. McCullough, E. Sidelnikov, C. R. Daniel, R. E. Rutherford, and A. Shaukat Effects of Supplemental Vitamin D and Calcium on Oxidative DNA Damage Marker in Normal Colorectal Mucosa: A Randomized Clinical Trial Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 280 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Thorson Progress in Cancer Care: A Rational Call To Do Better CA Cancer J Clin, January 1, 2010; 60(1): 7 - 11. [Full Text] [PDF]
|
|
|
|
|
|
M. Kagawa-Singer, A. Valdez Dadia, M. C. Yu, and A. Surbone Cancer, Culture, and Health Disparities: Time to Chart a New Course? CA Cancer J Clin, January 1, 2010; 60(1): 12 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Iniesta, J. Chien, M. Wicha, and S. D. Merajver One-Hit Effects and Cancer Cancer Prevention Research, January 1, 2010; 3(1): 12 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Freedland, C. D. Williams, and E. M. Masko Adiponectin and Prostate Cancer Mortality: To Be or Not to Be Skinny? Clin. Chem., January 1, 2010; 56(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Armstrong, E. Garrett-Mayer, R. de Wit, I. Tannock, and M. Eisenberger Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer Clin. Cancer Res., January 1, 2010; 16(1): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Su, K. I. Amiri, L. W. Horton, Y. Yu, G. D. Ayers, E. Koehler, M. C. Kelley, I. Puzanov, A. Richmond, and J. A. Sosman A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets Clin. Cancer Res., January 1, 2010; 16(1): 348 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vincenzi, D. Santini, A. Russo, R. Addeo, F. Giuliani, L. Montella, S. Rizzo, O. Venditti, A. M. Frezza, M. Caraglia, et al. Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib Oncologist, January 1, 2010; 15(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kawai, S. Sakano, Y. Suehiro, T. Okada, Y. Korenaga, T. Hara, K. Naito, H. Matsuyama, and Y. Hinoda Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma Ann. Onc., December 27, 2009; (2009) mdp577v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sharma Barrett's Esophagus N. Engl. J. Med., December 24, 2009; 361(26): 2548 - 2556. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge and E. P. Winer On Mammography -- More Agreement Than Disagreement N. Engl. J. Med., December 24, 2009; 361(26): 2499 - 2501. [Full Text] [PDF]
|
|
|
|
|
|
H. Fukushima, F. Koga, S. Kawakami, Y. Fujii, S. Yoshida, E. Ratovitski, B. Trink, and K. Kihara Loss of {Delta}Np63{alpha} Promotes Invasion of Urothelial Carcinomas via N-Cadherin/Src Homology and Collagen/Extracellular Signal-Regulated Kinase Pathway Cancer Res., December 15, 2009; 69(24): 9263 - 9270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mulshine and D. M. Jablons Volume CT for Diagnosis of Nodules Found in Lung-Cancer Screening N. Engl. J. Med., December 3, 2009; 361(23): 2281 - 2282. [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, A. Cassidy, J. Gu, G. L. Delclos, F. Zhen, H. Yang, M. A.T. Hildebrandt, J. Lin, Y. Ye, R. M. Chamberlain, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk Carcinogenesis, December 1, 2009; 30(12): 2047 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Niu, Y.-J. Huang, L.-E Wang, E. M. Sturgis, and Q. Wei Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck Carcinogenesis, December 1, 2009; 30(12): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. YE, P. XU, W. R. THRELFALL, R. JEN, H. LI, S.-H. LIN, C.-T. KUO, and Y. C. LIN Zeranol Enhances the Proliferation of Pre-adipocytes in Beef Heifers Anticancer Res, December 1, 2009; 29(12): 5045 - 5052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bonsib Renal Cystic Diseases and Renal Neoplasms: A Mini-Review Clin. J. Am. Soc. Nephrol., December 1, 2009; 4(12): 1998 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al. Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines Mayo Clin. Proc., December 1, 2009; 84(12): 1095 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mandelblatt, K. A. Cronin, S. Bailey, D. A. Berry, H. J. de Koning, G. Draisma, H. Huang, S. J. Lee, M. Munsell, S. K. Plevritis, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms Ann Intern Med, November 17, 2009; 151(10): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, J. Prescott, J. Sullivan-Halley, K. D. Henderson, H. Ma, E. T. Chang, C. A. Clarke, P. L. Horn-Ross, G. Ursin, and L. Bernstein Body Size, Recreational Physical Activity, and B-Cell Non-Hodgkin Lymphoma Risk Among Women in the California Teachers Study Am. J. Epidemiol., November 15, 2009; 170(10): 1231 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kashani-Sabet, S. Venna, M. Nosrati, J. Rangel, A. Sucker, F. Egberts, F. L. Baehner, J. Simko, S. P.L. Leong, C. Haqq, et al. A Multimarker Prognostic Assay for Primary Cutaneous Melanoma Clin. Cancer Res., November 15, 2009; 15(22): 6987 - 6992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Park, J. Koo, H. S. Park, J.-H. Kim, S.-Y. Choi, J. H. Lee, B.-W. Park, and K. S. Lee Expression of androgen receptors in primary breast cancer Ann. Onc., November 3, 2009; (2009) mdp510v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sidelnikov, R. M. Bostick, W. D. Flanders, Q. Long, and M. E. Seabrook Colorectal Mucosal Expression of MSH2 as a Potential Biomarker of Risk for Colorectal Neoplasms Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2965 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Stout Cancer Prevention in Physical Therapist Practice Physical Therapy, November 1, 2009; 89(11): 1119 - 1122. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ren, Z. Liu, Z. Miao, H. Liu, M. Subbarayan, F. T. Chin, L. Zhang, S. S. Gambhir, and Z. Cheng PET of Malignant Melanoma Using 18F-Labeled Metallopeptides J. Nucl. Med., November 1, 2009; 50(11): 1865 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective Clin. Cancer Res., November 1, 2009; 15(21): 6503 - 6510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Esserman, Y. Shieh, and I. Thompson Rethinking Screening for Breast Cancer and Prostate Cancer JAMA, October 21, 2009; 302(15): 1685 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Roy and L. K. Bianchi Differences in Colon Adenomas and Carcinomas Among Women and Men: Potential Clinical Implications JAMA, October 21, 2009; 302(15): 1696 - 1697. [Full Text] [PDF]
|
|
|
|
|
|
G. Ren, Z. Miao, H. Liu, L. Jiang, N. Limpa-Amara, A. Mahmood, S. S. Gambhir, and Z. Cheng Melanin-Targeted Preclinical PET Imaging of Melanoma Metastasis J. Nucl. Med., October 1, 2009; 50(10): 1692 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Schuetze and S. Patel Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy? Oncologist, October 1, 2009; 14(10): 1003 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lieberman Screening for Colorectal Cancer N. Engl. J. Med., September 17, 2009; 361(12): 1179 - 1187. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cersosimo Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1 Am. J. Health Syst. Pharm., September 1, 2009; 66(17): 1525 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Grant, R. Elk, B. Ferrell, R. S. Morrison, and C. F. von Gunten Current Status of Palliative Care--Clinical Implementation, Education, and Research CA Cancer J Clin, September 1, 2009; 59(5): 327 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chang and C. L. Collie The Future of Cancer Prevention: Will Our Workforce Be Ready? Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2348 - 2351. [Full Text] [PDF]
|
|
|
|
|
|
P. N. Munster and J. T. Carpenter Estradiol in Breast Cancer Treatment: Reviving the Past JAMA, August 19, 2009; 302(7): 797 - 798. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
